Warfarin use and prevalence of coronary artery calcification assessed by multislice computed tomography

Chandrasekar Palaniswamy, Wilbert S. Aronow, Arunabh Sekhri, Sreedhar Adapa, Chul Ahn, Tarunjit Singh, Bharat Malhotra, Robert Lerner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Warfarin inhibits the synthesis and function of matrix Gla protein, a vitamin K-dependent protein, which is a potent inhibitor of tissue calcification. We had earlier reported the association of warfarin use with valvular calcification in patients with nonvalvular atrial fibrillation. The aim of our present study was to investigate the association of warfarin use with the presence and severity of coronary artery calcification. A total of 233 patients underwent computed tomography scan (CT) at our institution for the assessment of coronary artery calcium score (CACS). Of 233 patients, the mean age was 63 years, 28 patients (12%) were treated with warfarin, and 205 patients (88%) were not on warfarin. Based on their total CACS, the patients were subsequently stratified into 59 with no coronary calcium (CACS = 0), 63 with low CACS (1-100), 49 with moderate CACS (101-400), 33 with severe CACS (410-1000), and 29 with very severe CACS (>1000). The χ test and Student t-Test were used for the comparison of categorical and continuous variables, respectively, between warfarin users and nonusers. Using the variables age, gender, race, smoking, hypertension, diabetes, dyslipidemia, glomerular filtration rate, calcium-phosphorus product, alkaline phosphatase, use of aspirin, beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins, stepwise logistic regression analysis did not show any association of coronary calcification with use of warfarin. In our study, warfarin use was not associated with a higher prevalence or severity of CACS assessed by coronary computed tomography.

Original languageEnglish (US)
Pages (from-to)148-151
Number of pages4
JournalAmerican Journal of Therapeutics
Volume21
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Multidetector Computed Tomography
Warfarin
Coronary Vessels
Calcium
Tomography
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Vitamin K
Angiotensin Receptor Antagonists
Dyslipidemias
Glomerular Filtration Rate
Angiotensin-Converting Enzyme Inhibitors
Atrial Fibrillation
Phosphorus
Aspirin
Alkaline Phosphatase
Logistic Models
Smoking
Regression Analysis
Students
Hypertension

Keywords

  • calcification
  • computed tomography
  • coronary artery calcium score
  • warfarin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Warfarin use and prevalence of coronary artery calcification assessed by multislice computed tomography. / Palaniswamy, Chandrasekar; Aronow, Wilbert S.; Sekhri, Arunabh; Adapa, Sreedhar; Ahn, Chul; Singh, Tarunjit; Malhotra, Bharat; Lerner, Robert.

In: American Journal of Therapeutics, Vol. 21, No. 3, 2014, p. 148-151.

Research output: Contribution to journalArticle

Palaniswamy, Chandrasekar ; Aronow, Wilbert S. ; Sekhri, Arunabh ; Adapa, Sreedhar ; Ahn, Chul ; Singh, Tarunjit ; Malhotra, Bharat ; Lerner, Robert. / Warfarin use and prevalence of coronary artery calcification assessed by multislice computed tomography. In: American Journal of Therapeutics. 2014 ; Vol. 21, No. 3. pp. 148-151.
@article{4c097c3cc852438e874e41f85ac42996,
title = "Warfarin use and prevalence of coronary artery calcification assessed by multislice computed tomography",
abstract = "Warfarin inhibits the synthesis and function of matrix Gla protein, a vitamin K-dependent protein, which is a potent inhibitor of tissue calcification. We had earlier reported the association of warfarin use with valvular calcification in patients with nonvalvular atrial fibrillation. The aim of our present study was to investigate the association of warfarin use with the presence and severity of coronary artery calcification. A total of 233 patients underwent computed tomography scan (CT) at our institution for the assessment of coronary artery calcium score (CACS). Of 233 patients, the mean age was 63 years, 28 patients (12{\%}) were treated with warfarin, and 205 patients (88{\%}) were not on warfarin. Based on their total CACS, the patients were subsequently stratified into 59 with no coronary calcium (CACS = 0), 63 with low CACS (1-100), 49 with moderate CACS (101-400), 33 with severe CACS (410-1000), and 29 with very severe CACS (>1000). The χ test and Student t-Test were used for the comparison of categorical and continuous variables, respectively, between warfarin users and nonusers. Using the variables age, gender, race, smoking, hypertension, diabetes, dyslipidemia, glomerular filtration rate, calcium-phosphorus product, alkaline phosphatase, use of aspirin, beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins, stepwise logistic regression analysis did not show any association of coronary calcification with use of warfarin. In our study, warfarin use was not associated with a higher prevalence or severity of CACS assessed by coronary computed tomography.",
keywords = "calcification, computed tomography, coronary artery calcium score, warfarin",
author = "Chandrasekar Palaniswamy and Aronow, {Wilbert S.} and Arunabh Sekhri and Sreedhar Adapa and Chul Ahn and Tarunjit Singh and Bharat Malhotra and Robert Lerner",
year = "2014",
doi = "10.1097/MJT.0b013e318249a1c6",
language = "English (US)",
volume = "21",
pages = "148--151",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Warfarin use and prevalence of coronary artery calcification assessed by multislice computed tomography

AU - Palaniswamy, Chandrasekar

AU - Aronow, Wilbert S.

AU - Sekhri, Arunabh

AU - Adapa, Sreedhar

AU - Ahn, Chul

AU - Singh, Tarunjit

AU - Malhotra, Bharat

AU - Lerner, Robert

PY - 2014

Y1 - 2014

N2 - Warfarin inhibits the synthesis and function of matrix Gla protein, a vitamin K-dependent protein, which is a potent inhibitor of tissue calcification. We had earlier reported the association of warfarin use with valvular calcification in patients with nonvalvular atrial fibrillation. The aim of our present study was to investigate the association of warfarin use with the presence and severity of coronary artery calcification. A total of 233 patients underwent computed tomography scan (CT) at our institution for the assessment of coronary artery calcium score (CACS). Of 233 patients, the mean age was 63 years, 28 patients (12%) were treated with warfarin, and 205 patients (88%) were not on warfarin. Based on their total CACS, the patients were subsequently stratified into 59 with no coronary calcium (CACS = 0), 63 with low CACS (1-100), 49 with moderate CACS (101-400), 33 with severe CACS (410-1000), and 29 with very severe CACS (>1000). The χ test and Student t-Test were used for the comparison of categorical and continuous variables, respectively, between warfarin users and nonusers. Using the variables age, gender, race, smoking, hypertension, diabetes, dyslipidemia, glomerular filtration rate, calcium-phosphorus product, alkaline phosphatase, use of aspirin, beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins, stepwise logistic regression analysis did not show any association of coronary calcification with use of warfarin. In our study, warfarin use was not associated with a higher prevalence or severity of CACS assessed by coronary computed tomography.

AB - Warfarin inhibits the synthesis and function of matrix Gla protein, a vitamin K-dependent protein, which is a potent inhibitor of tissue calcification. We had earlier reported the association of warfarin use with valvular calcification in patients with nonvalvular atrial fibrillation. The aim of our present study was to investigate the association of warfarin use with the presence and severity of coronary artery calcification. A total of 233 patients underwent computed tomography scan (CT) at our institution for the assessment of coronary artery calcium score (CACS). Of 233 patients, the mean age was 63 years, 28 patients (12%) were treated with warfarin, and 205 patients (88%) were not on warfarin. Based on their total CACS, the patients were subsequently stratified into 59 with no coronary calcium (CACS = 0), 63 with low CACS (1-100), 49 with moderate CACS (101-400), 33 with severe CACS (410-1000), and 29 with very severe CACS (>1000). The χ test and Student t-Test were used for the comparison of categorical and continuous variables, respectively, between warfarin users and nonusers. Using the variables age, gender, race, smoking, hypertension, diabetes, dyslipidemia, glomerular filtration rate, calcium-phosphorus product, alkaline phosphatase, use of aspirin, beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins, stepwise logistic regression analysis did not show any association of coronary calcification with use of warfarin. In our study, warfarin use was not associated with a higher prevalence or severity of CACS assessed by coronary computed tomography.

KW - calcification

KW - computed tomography

KW - coronary artery calcium score

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=84900821108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900821108&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e318249a1c6

DO - 10.1097/MJT.0b013e318249a1c6

M3 - Article

VL - 21

SP - 148

EP - 151

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 3

ER -